ArticleJAMA2015
Association of Cardiometabolic Multimorbidity With Mortality.
Article in JAMA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 595 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Canagliflozin Attenuates CMR-Quantified Myocardial Fibrosis in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Advanced Type 2 Diabetes
Risk Profiling for Patients With Isolated or Combined Coronary and Cerebral Ischemia, and Their Current Status of Risk Factors Control
Magnetocardiography Endocrine Registry
Who cites it
595 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,076 citations in OpenAlex.
- Prevalence of cardiometabolic diseases in Sub-Saharan Africa: a systematic review and meta-analysis.Global health action · 2025Pooled it
- The Effects of Time-Restricted Feeding and Exercise on Cardiometabolic Health in Sedentary Older Adults: A Randomized Controlled Trial.Medicine and science in sports and exercise · 2026Trial
- Long-term cumulative exposure and change patterns of CTI-FI predict the risk of cardiometabolic multimorbidity in middle-aged and older Chinese adults.Journal of diabetes and metabolic disorders · 2026Article
- Association of long-term depressive burden with incident cardiometabolic multimorbidity: a prospective study in middle-aged and older adults across three continents.Journal of global health · 2026Article
- Estimated Cardiorespiratory Fitness and Incident Cardiometabolic Multimorbidity in Older Adults: A Prospective Cohort Study.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Joint Trajectories of Physical Activity and Depressive Symptoms and Incident Cardiometabolic Multimorbidity: A Multi-Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Clinical trials in a dish: cardiometabolic drug development with biological and digital twins.The Journal of clinical investigation · 2026Review
- Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- A Cross-Nationally Validated Nomogram for Cardiometabolic Multimorbidity in Overweight/Obese Older Adults: CHARLS and HRS Cohorts.Diabetes, obesity & metabolism · 2026Article
- Weekend Warrior and other physical activity patterns: mortality and life expectancy in individuals with cardiometabolic multimorbidity.Journal of exercise science and fitness · 2026Article
- Effectiveness and safety of Janus Kinase inhibitors in patients with rheumatoid arthritis, results from a multicenter observational "real-life" GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study.Clinical rheumatology · 2026Article
- Association between body roundness index and progression of cardio-renal-metabolic diseases using multistate models.GeroScience · 2026Article
- Composite C-reactive protein-triglyceride-glucose adiposity indices and incident cardiovascular-liver-metabolic multimorbidity: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Integrating social and cardiometabolic risk factors in predicting cardiometabolic multimorbidity: a Bayesian model development and internal validation in Swedish middle-aged adults.Scientific reports · 2026Article
- Bidirectional associations between loneliness and physical multimorbidity and the mediating role of social inactivity.Nature communications · 2026Article
- Neutrophil-to-high-density lipoprotein cholesterol ratio and prevalent cardiometabolic multimorbidity in older adults: an exploratory cross-sectional analysis.BMC endocrine disorders · 2026Article
- Colorectal cancer outcomes show relationships with the type and extent of vascular complications in individuals with diabetes: A population-based study.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Sustained estimated VLDL-C exposure is associated with cardiometabolic multimorbidity and foam cell dysfunction: evidence from prospective cohorts andJournal of geriatric cardiology : JGC · 2026Article
- Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Overview of the Prevalence of Noncommunicable Chronic Diseases in the Brazilian Population Reporting Physical Inactivity.International journal of environmental research and public health · 2026Article
535 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedAuthor's Middle Initials Missing in Byline.2015 · Leening, Maarten [corrected to Leening, Maarten J G]
Authors and funding
90 authors at 20 institutions in 15 countries.
Funding
Abstract
importanceThe prevalence of cardiometabolic multimorbidity is increasing.
objectiveTo estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND
participantsAge- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy.
resultsIn participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.